Miralles-López Juan Carlos, Alvarez-Gutiérrez Francisco J, Delgado-Romero Julio, Quirce Santiago, Soto-Campos Jose Gregorio, Andújar-Espinosa Ruben, Cabrejos-Perotti Sheila, Castilla-Martínez Manuel, Flores-Martín Isabel, Pajarón-Fernández Manuel José, Valverde-Molina José
Allergy Department, University General Hospital Reina Sofia, Murcia, Spain.
Severe Asthma Association of the Region of Murcia. ASGRAMUR, Murcia, Spain.
J Asthma Allergy. 2024 Nov 14;17:1163-1171. doi: 10.2147/JAA.S488764. eCollection 2024.
With the advent of biological therapies, emerging concepts regarding establishing new targets in asthma management, such as disease modification, have entered the debate among the scientific community. The definitions that form the conceptual basis of this goal need to be agreed upon.
A multidisciplinary expert group was assembled as the steering committee. A systematic literature review was conducted to identify the scientific background for constructing appropriate definitions. Based on the literature review and the clinical experience of the experts, the committee built a list of statements that could be applied to establish the definition of disease modification in asthma. After that, a Delphi validation was performed to assess the appropriateness of the list of statements. The questionnaire included a total of 22 statements, divided into "Essential criteria for disease modification in asthma" (5 statements) and "Disease modification indicators and other considerations" (17 statements). Panelists used a 9-point Likert scale to measure agreement on each statement. The cut-off point for high consensus was defined as a minimum score of 7 and had to be reached by at least two-thirds of the experts.
A total of 192 asthma experts voted on statements anonymously. Of those, 104 (54%) were Pneumologists, 65 (34%) were allergologists, and 23 (12%) were Pediatricians. An interim analysis of round 1 data was performed. All statements reached consensus on the first round, with a median score above 7 in all cases.
In conclusion, in this Delphi study, a large number of experts in the management of severe asthma from different specialties agreed on the clinical-functional and pathophysiological aspects to be considered in order to try to achieve disease modification.
随着生物疗法的出现,关于在哮喘管理中确立新目标(如疾病修饰)的新观念已进入科学界的讨论。构成这一目标概念基础的定义需要达成共识。
组建了一个多学科专家组作为指导委员会。进行了系统的文献综述,以确定构建适当定义的科学背景。基于文献综述和专家的临床经验,委员会列出了一系列可用于确立哮喘疾病修饰定义的陈述。之后,进行了德尔菲验证,以评估这些陈述列表的适当性。问卷总共包括22条陈述,分为“哮喘疾病修饰的基本标准”(5条陈述)和“疾病修饰指标及其他考虑因素”(17条陈述)。小组成员使用9点李克特量表来衡量对每条陈述的认同程度。高度共识的临界点定义为最低得分为7分,且至少三分之二的专家必须达到该分数。
共有192名哮喘专家对陈述进行了匿名投票。其中,104名(54%)是肺病学家,65名(34%)是过敏症专科医生,23名(12%)是儿科医生。对第一轮数据进行了中期分析。所有陈述在第一轮都达成了共识,所有情况下中位数得分均高于7分。
总之,在这项德尔菲研究中,来自不同专业的大量重度哮喘管理专家就为尝试实现疾病修饰而需考虑的临床功能和病理生理方面达成了共识。